Skip to content

Efficacy and Safety of Cementless Oxford Unicompartmental Knee Replacement in the Treatment of Knee Arthritis: a Randomized Controlled Pilote Trial

Efficacy and Safety of Cementless Oxford Unicompartmental Knee Replacement in the Treatment of Knee Arthritis:a Randomized Controlled Pilote Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020370
Enrollment
Unknown
Registered
2018-12-27
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Arthritis

Interventions

Cementless Oxford Unicompartmental Knee Replacement Group:Replace cemented prosthesis with cementless prosthesis
Control:Perform cemented Oxford unicompartmental knee replacement

Sponsors

Shanghai Yangpu District Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Anteromedial osteoarthritis, no extraarticular deformities; 2. Anterior cruciate ligament and collateral ligament function intact; 3. Lateral compartment cartilage thickness intact; 4. The valgus stress can be corrected when the varus deformity is in the 20 °position of flexion; 5. Flexion ankylosis less than 15 degree; 6. Patients or their guardians should agree with this clinical trail and sign the medical informed consent.

Exclusion criteria

Exclusion criteria: 1. Unavailable or limited legal capacity; 2. Infection, tuberculosis or tumor-related disease of the knee; 3.Patients who had a friable, fragmented or absent anterior cruciate ligament (ACL) or had undergone previous/simultaneous ACL reconstruction or previous high tibial osteotomy; 4. Important organs with severe diseases; 5. Person with severe bleeding or bleeding tendencies, such as active peptic ulcers, intracranial hemorrhage, trauma, or other bleeding5. With suspected or definite alcohol, drug abuse history; 6. Suffer from autoimmune diseases such as rheumatoid arthritis; 7. Patients at active stages of infectious or other diseases such as hepatitis A, hepatitis B, AIDS, tuberculosis, and some connective tissue diseases7. Patients with IPAH responding to acute pulmonary vasodilator testing; 8. Patients with any other conditions considered cannot be recruited.

Design outcomes

Primary

MeasureTime frame
Oxford Knee Seessment;Range of Motion;Operation time;Incidence of Radiolucent Lines;

Countries

China

Contacts

Public ContactYihui Tu

SHANGHAI YANGPU DISTRICT CENTRAL HOSPITAL

tuyihui2010@126.com+86 13818148186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026